In IDH mutant gliomas, it is well known that 1p/19q co-deleted gliomas (oligodendrogliomas in the revised WHO classification) have better prognoses; our previous study revealed that IDH mutant gliomas with wild-type TP53, which are almost identical to 1p/19q co-deleted gliomas, showed significantly better prognoses than IDH and TP53 mutant gliomas (astrocytomas in the revised WHO classification) [8]. This evidence concerns the gene TP53 and central nervous system cancer.